Trial: 201802012

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

Phase

I

Principal Investigator

Govindan, Ramaswamy

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov